Form 4: Director Kevin Buehler Receives RSU Grant at Precision Bio

Precision BioSciences director Kevin Buehler was granted 20,979 restricted stock units as part of standard equity compensation.

Summary

• Director Kevin Buehler received a grant of 20,979 restricted stock units (RSUs) on June 3, 2026.
• Each RSU represents a contingent right to receive one share of Precision BioSciences common stock.
• The grant is subject to vesting conditions based on continued service to the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and settlement of the RSUs.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The RSUs will vest on the earlier of June 3, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The vesting schedule aligns with typical one-year cliff vesting cycles seen in similar public companies.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future settlement of the RSUs.

Next Steps

• Vesting of the RSUs on June 3, 2027, or the day before the next annual meeting.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Equity Compensation, Director Compensation